| Name | Cedirogant |
|---|
| Description | Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
RORγt[1] |
| In Vitro | The transcription factor retinoic acid-related orphan receptor gamma t (RORγt) has been identified as the master regulator of TH17 cell differentiation and IL-17/22 production and is therefore an attractive target for the treatment of inflammatory diseases. Cedirogant (ABBV-157) has the potential for chronic plaque psoriasis research[1]. |
| References |
| Molecular Formula | C24H20Cl3F3N2O3 |
|---|---|
| Molecular Weight | 547.78 |